6-N-(4-Monomethoxytrityl)-9-(3,5-di-O-benzoyl-2-deoxy-beta-L-threo-pentofuranosyl)adenine | 233681-07-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 6-N-(4-Monomethoxytrityl)-9-(3,5-di-O-benzoyl-2-deoxy-beta-L-threo-pentofuranosyl)adenine
• 英文别名: [(2S,3S,5S)-3-benzoyloxy-5-[6-[[(4-methoxyphenyl)-diphenylmethyl]amino]purin-9-yl]oxolan-2-yl]methyl benzoate
• CAS: 233681-07-7
• 化学式: C₄₄H₃₇N₅O₆
• 分子量: 731.808
• InChiKey: ZYWAJXNVAJQQQR-QXUSSCGESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.4
• 重原子数：
  55
• 可旋转键数：
  14
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  127
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  6-N-(4-Monomethoxytrityl)-9-(3,5-di-O-benzoyl-2-deoxy-beta-L-threo-pentofuranosyl)adenine 在 吡啶 、 甲醇 、 氨 作用下， 生成 (2S,3S,5S)-2-[(4-Methoxy-phenyl)-diphenyl-methoxymethyl]-5-(6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-purin-9-yl)-tetrahydro-furan-3-ol
  参考文献：
  名称：

  Unnatural β-L-Enantiomers of Nucleoside Analogues as Potent Anti-Hepatitis B Virus Agents

  摘要：

  Several 2'- or 3'-substituted 2',3'-dideoxy-beta-L-nucleosides bearing adenine as the base were stereospecifically synthesized and their antiviral properties examined. Two of them, namely 2'-azido- and 3'-azido-2',3'-dideoxy-beta-L-adenosine (2'-N-3-beta-L-ddA and 3'-N-3-beta-L-ddA) were found to have some anti-hepatitis B virus (HBV) activity in cell culture.

  DOI：

  10.1080/07328319808004708
• 作为产物：
  描述：

  9-(2-O-acetyl-3,5-di-O-benzoyl-β-L-xylofuranosyl)adenine 在 吡啶 、 4-二甲氨基吡啶 、 偶氮二异丁腈 、 (Me₃Si(3SiH 、 一水合肼 、 硫代氯甲酸苯酯 作用下， 以 吡啶 、 溶剂黄146 为溶剂， 生成 6-N-(4-Monomethoxytrityl)-9-(3,5-di-O-benzoyl-2-deoxy-beta-L-threo-pentofuranosyl)adenine
  参考文献：
  名称：

  Unnatural β-L-Enantiomers of Nucleoside Analogues as Potent Anti-Hepatitis B Virus Agents

  摘要：

  Several 2'- or 3'-substituted 2',3'-dideoxy-beta-L-nucleosides bearing adenine as the base were stereospecifically synthesized and their antiviral properties examined. Two of them, namely 2'-azido- and 3'-azido-2',3'-dideoxy-beta-L-adenosine (2'-N-3-beta-L-ddA and 3'-N-3-beta-L-ddA) were found to have some anti-hepatitis B virus (HBV) activity in cell culture.

  DOI：

  10.1080/07328319808004708

文献信息

• Beta-L-2'-deoxy-nucleosides for the treatment of hepatitis B
  申请人：Centre National da la Reserche Scientifique

  公开号：US20030220290A1

  公开（公告）日：2003-11-27

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula: 1 wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  本发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予一种抗HBV生物活性2'-脱氧-β-L-核糖呋喃核苷或其药学上可接受的盐或前药的有效量，其中2'-脱氧-β-L-核糖呋喃核苷的化学式为：1，其中R选自H、直链、支链或环烷基、CO-烷基、CO-芳基、CO-烷氧基烷基、CO-芳氧基烷基、CO-取代芳基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、氨基酸残基、单、二或三磷酸盐或磷酸衍生物；BASE是嘌呤或嘧啶碱基，可以选择性地被取代。2'-脱氧-β-L-核糖呋喃核苷或其药学上可接受的盐或前药可以单独使用或与另一种2'-脱氧-β-L-核糖呋喃核苷或另一种抗乙型肝炎药物联合使用。
• Methods of treating hepatitis delta virus infection with beta-l-2'-deoxy-nucleosides
  申请人：——

  公开号：US20020035085A1

  公开（公告）日：2002-03-21

  A method and composition for treating a host infected with hepatitis D comprising administering an effective hepatitis D treatment amount of a described 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof.

  一种治疗患有丙型肝炎的宿主的方法和组合物，包括给予一定量的2'-脱氧-&bgr;-L-erythro-戊糖核苷或其药用可接受的盐或前药，以有效治疗丙型肝炎。
• Beta-L-2'deoxy-nucleosides for the treatment of hepatitis B
  申请人：——

  公开号：US20030225028A1

  公开（公告）日：2003-12-04

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula: 1 wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  本发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予一种抗HBV生物活性的2'-去氧-&bgr;-L-核糖核苷或其药用盐或前药的有效量，其中2'-去氧-&bgr;-L-核糖核苷具有以下公式：1其中R选自H、直链、支链或环烷基、CO-烷基、CO-芳基、CO-烷氧基烷基、CO-芳氧基烷基、CO-取代芳基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、氨基酸残基、单、二或三磷酸盐或磷酸衍生物；BASE是一种可以选择性地取代的嘌呤或嘧啶碱基。2'-去氧-&bgr;-L-核糖核苷或其药用盐或前药可以单独或与另一种2'-去氧-&bgr;-L-核糖核苷或其他抗乙型肝炎药物联合使用。
• beta-L-2'-deoxy-nucleosides for the treatment of hepatitis B
  申请人：Gosselin Gilles

  公开号：US20060084624A1

  公开（公告）日：2006-04-20

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-eythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  本发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予一种抗HBV生物活性2'-脱氧-β-L-erythro-戊糖核苷或其药学可接受的盐或前药的有效量，其中2'-脱氧-β-L-erythro-戊糖核苷的化学式为：其中R选自H、直链、支链或环烷基、CO-烷基、CO-芳基、CO-烷氧基烷基、CO-芳氧基烷基、CO-取代芳基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、氨基酸残基、单磷酸、二磷酸或三磷酸，或磷酸衍生物；BASE是一种可以选择性地被取代的嘌呤或嘧啶碱基。2'-脱氧-β-L-erythro-戊糖核苷或其药学可接受的盐或前药可以单独或与另一种2'-脱氧-β-L-erythro-戊糖核苷或另一种抗乙型肝炎药物联合给予。
• &bgr;-L-2′-deoxy-nucleosides for the treatment of hepatitis B
  申请人：Novirio Pharmaceuticals Limited

  公开号：US06395716B1

  公开（公告）日：2002-05-28

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  本发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予有效量的抗乙型肝炎病毒生物活性2'-去氧-β-L-核糖呋喃核苷或其药学上可接受的盐或前药，其中2'-去氧-β-L-核糖呋喃核苷的化学式为：其中R选自H，直链、支链或环烷基，CO-烷基、CO-芳基、CO-烷氧基烷基、CO-芳氧基烷基、CO-取代芳基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、氨基酸残基、单、二或三磷酸盐或磷酸衍生物；BASE为一种嘌呤或嘧啶碱基，可以选择性地取代。2'-去氧-β-L-核糖呋喃核苷或其药学上可接受的盐或前药可以单独或与另一种2'-去氧-β-L-核糖呋喃核苷或另一种抗乙型肝炎药物联合给予。